Ignite Creation Date:
2025-12-24 @ 4:20 PM
Ignite Modification Date:
2025-12-29 @ 1:56 AM
Study NCT ID:
NCT07183566
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-09-19
First Post:
2025-09-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
CT Volume Measurement of Hepatocellular Carcinoma
Sponsor:
Assiut University
Organization:
Study Overview
Official Title:
Ct Volume Measurement of Hepatocellular Carcinoma After Transarterial Chemoembolization (TACE) or Microwave Ablation (MWA)
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to evaluate the role of CT volumetric measurement in assessing treatment response of hepatocellular carcinoma (HCC) following trans arterial chemoembolization (TACE) or microwave ablation (MWA)
Detailed Description:
Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer and a major contributor to cancer-related mortality worldwide (1). Conventional curative interventions for HCC encompass liver transplantation, hepatic resection, and thermal ablation. Regrettably, fewer than 30% of patients qualify for surgery upon diagnosis, and many tumor-related characteristics, including size and location, may inhibit the application of thermal ablative methods .
In these cases, locoregional therapies such as transarterial chemoembolization (TACE) and microwave ablation (MWA) play a pivotal role. Both techniques aim to achieve local tumor control and improve patient survival. TACE induces ischemic necrosis through targeted delivery of chemotherapeutic agents combined with arterial embolization, whereas MWA achieves tumor destruction by generating high-frequency electromagnetic waves that produce thermal coagulative necrosis. Accurate assessment of treatment response is essential for guiding clinical decisions and predicting outcomes. Conventional imaging-based response criteria, such as RECIST and mRECIST, primarily focus on changes in lesion diameter. However, these methods may not fully reflect the extent of tumor necrosis or viable residual tissue . In this context, CT-based volumetric measurements have emerged as a more objective and sensitive tool for evaluating therapeutic response after locoregional treatment. Volumetric analysis provides a three-dimensional assessment of tumor burden and may bet ter correlate with treatment efficacy and prognosis compared to traditional linear measurements. Therefore, this study aims to investigate the role of CT volumetric measurement of HCC after TACE or microwave ablation in evaluating treatment response and predicting clinical outcomes .
In these cases, locoregional therapies such as transarterial chemoembolization (TACE) and microwave ablation (MWA) play a pivotal role. Both techniques aim to achieve local tumor control and improve patient survival. TACE induces ischemic necrosis through targeted delivery of chemotherapeutic agents combined with arterial embolization, whereas MWA achieves tumor destruction by generating high-frequency electromagnetic waves that produce thermal coagulative necrosis. Accurate assessment of treatment response is essential for guiding clinical decisions and predicting outcomes. Conventional imaging-based response criteria, such as RECIST and mRECIST, primarily focus on changes in lesion diameter. However, these methods may not fully reflect the extent of tumor necrosis or viable residual tissue . In this context, CT-based volumetric measurements have emerged as a more objective and sensitive tool for evaluating therapeutic response after locoregional treatment. Volumetric analysis provides a three-dimensional assessment of tumor burden and may bet ter correlate with treatment efficacy and prognosis compared to traditional linear measurements. Therefore, this study aims to investigate the role of CT volumetric measurement of HCC after TACE or microwave ablation in evaluating treatment response and predicting clinical outcomes .
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: